Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Abstract: A light tower includes a base, an extendible mast coupled to the base, a battery pack supported on the base and including a plurality of lithium-ion battery cells, a light assembly including a plurality of light emitting diodes electrically coupled to the battery pack, a display configured to receive inputs and display information, and a controller in communication with the battery pack, the light assembly, and the display. The configured being to: receive a light intensity change input from the display, change a power provided by the battery pack to the light emitting diodes in response to the light intensity change input, and display on the display a change in runtime resulting from the change of the power provided by the battery pack to the light emitting diodes.

Abstract: Provided herein is a high throughput screening method for identifying guide RNAs (gRNAs) useful for editing a target RNA, wherein the editing is mediated by an RNA editing entity (e.g., a native human adenosine deaminase enzyme for a human subject).

Abstract: A site connectivity system includes a first connectivity module configured to be coupled to a first machine, a second connectivity module configured to be coupled to a second machine, and a third connectivity module configured to be coupled to a third machine. The third machine is a different type of machine than at least one of the first machine or the second machine. The first connectivity module and the second connectivity module are configured to establish a site network at a site. The third connectivity module is configured to join the site network and transmit data regarding the third machine to the first connectivity module through the site network.

Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Abstract: A hybrid light tower includes an engine, a permanent magnet generator configured to be driven by the engine, a battery pack including a plurality of lithium-ion battery cells, an extendible mast configured to move between a lowered position and a raised position, and a light assembly including a plurality of light emitting diodes. The generator is configured to produce a first DC power. The battery pack is directly electrically coupled to the generator to receive the first DC power from the generator to charge the battery pack. The light assembly is coupled to the mast and the light emitting diodes electrically coupled to the battery pack to receive a second DC power from the battery pack. The light tower does not include a battery charger connected to the battery pack.

Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

Abstract: Provided herein are engineered latent guide RNAs that bind target RNAs to form a guide-target RNA scaffold and are substrates for RNA editing entities, which chemically modify the base of a nucleotide of the target RNA. Also provided herein are compositions, vectors, and cells comprising the engineered latent guide RNAs disclosed herein and methods of use thereof.

Abstract: Provided is a seamless composite roofing system for a gravel built up surface. The system includes a first fluid application flood coat of bentonite emulsion applied over a gravel built up surface at a rate of 15 gallons per 100 square feet and a second fluid application flood coat of bentonite emulsion applied at a rate of 10 gallons per 100 square feet. The second flood coat includes approximately 3 to 6 pounds of chopped reinforced fiberglass per 100 square feet, and is applied over the first flood coat after the first flood coat cures. A fiberglass reinforcement layer with approximately 3 to 6 pounds chopped reinforced fiberglass per 100 square feet is applied over an area surrounding any roof top penetrations, followed by an elastic trowel grade mastic layer. An asphalt primer is then applied over the second flood coat, followed by a reflective Energy Star Rated top coat.

Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Abstract: This disclosure relates to binding agents, e.g., antibody molecules, that bind hemagglutinin protein of influenza viruses, and methods of their use.

Abstract: Provided herein are compositions and methods that can be utilized to ameliorate, treat, or at least partially eliminate diseases and conditions that can arise from genomic mutations. Subject compositions and methods can be used to edit RNA to ameliorate, treat, or at least partially eliminate the disease and conditions in a subject.

Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.

Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

Abstract: Provided is a seamless composite roofing system for a gravel built up surface. The system includes a first fluid application flood coat of bentonite emulsion applied over a gravel built up surface at a rate of 15 gallons per 100 square feet and a second fluid application flood coat of bentonite emulsion applied at a rate of 10 gallons per 100 square feet. The second flood coat includes approximately 3 to 6 pounds of chopped reinforced fiberglass per 100 square feet, and is applied over the first flood coat after the first flood coat cures. A fiberglass reinforcement layer with approximately 3 to 6 pounds chopped reinforced fiberglass per 100 square feet is applied over an area surrounding any roof top penetrations, followed by an elastic trowel grade mastic layer. An asphalt primer is then applied over the second flood coat, followed by a reflective Energy Star Rated top coat.

Abstract: An automated method adapted to associate a consumer with a rewards program is described. The method includes: providing a bill to the consumer using a processing device; receiving payment information regarding the consumer; receiving biographical information regarding the consumer; and updating information regarding a user account associated with the rewards program. A software application adapted to process a payment and update rewards program information includes sets of instructions for: generating a bill for a set of goods or services provided to a consumer; receiving a method of payment from the consumer; determining an account associated with the method of payment; and updating the rewards program information associated with the account. An automated method of facilitating a redemption associated with a rewards program includes: receiving a bill associated with a consumer purchase; receiving payment information from the consumer; and applying at least a portion of a redemption balance to the bill.

Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

Abstract: Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.

Abstract: An automated method adapted to associate a consumer with a rewards program is described. The method includes: providing a bill to the consumer using a processing device; receiving payment information regarding the consumer; receiving biographical information regarding the consumer; and updating information regarding a user account associated with the rewards program. A software application adapted to process a payment and update rewards program information includes sets of instructions for: generating a bill for a set of goods or services provided to a consumer; receiving a method of payment from the consumer; determining an account associated with the method of payment; and updating the rewards program information associated with the account. An automated method of facilitating a redemption associated with a rewards program includes: receiving a bill associated with a consumer purchase; receiving payment information from the consumer; and applying at least a portion of a redemption balance to the bill.